InspireMD (NYSE:NSPR) Price Target Lowered to $4.00 at Piper Sandler

InspireMD (NYSE:NSPR) had its target price reduced by analysts at Piper Sandler from $4.50 to $4.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler’s price objective suggests a potential upside of 64.61% from the stock’s current price.

Separately, StockNews.com started coverage on InspireMD in a report on Monday, May 5th. They issued a “sell” rating on the stock.

InspireMD Stock Down 5.8%

NSPR stock opened at $2.43 on Monday. InspireMD has a twelve month low of $2.07 and a twelve month high of $3.80. The stock’s 50 day moving average is $2.64 and its 200-day moving average is $2.74. The firm has a market capitalization of $74.44 million, a PE ratio of -3.24 and a beta of 0.62.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Brown Advisory Inc. bought a new position in shares of InspireMD during the first quarter valued at about $27,000. Uniting Wealth Partners LLC bought a new stake in InspireMD during the first quarter worth $27,000. Renaissance Technologies LLC bought a new stake in InspireMD during the fourth quarter worth $27,000. XTX Topco Ltd bought a new stake in InspireMD during the first quarter worth $38,000. Finally, Legato Capital Management LLC bought a new stake in InspireMD during the fourth quarter worth $47,000. 44.78% of the stock is owned by institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.